Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate progression free survival, transplant-related
morbidity (TRM) at day +100 and at +365, overall survival and incidence of acute and chronic
GVHD in refractory/early relapsed aggressive B-cell non Hodgkin lymphomas patients treated
with allogeneic Transplantation after a conditioning with Thiotepa, Busulfan and fludarabin.